Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/11620
Título : | Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease | Autor : | Pérez Lloret, Santiago Cardinali, Daniel Pedro |
Palabras clave : | MELATONINA; ENFERMEDAD DE PARKINSON; ENVEJECIMIENTO; NEURODEGENERACION; ENFERMEDADES NEURODEGENERATIVAS; TRATAMIENTO MEDICO | Fecha de publicación : | 2021 | Editorial : | Frontiers Media | Cita : | Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620 | Resumen : | Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect. | URI : | https://repositorio.uca.edu.ar/handle/123456789/11620 | ISSN : | 1663-9812 | Disciplina: | MEDICINA | DOI: | 10.3389/fphar.2021.650597 | Derechos: | Acceso abierto |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
melatonin-chronobiotic-cytoprotective-agent.pdf | 936,29 kB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
137
comprobado en 27-abr-2024
Descarga(s)
150
comprobado en 27-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons